• Artwork must be original and created by the submitter
• Maximum of two submissions per artist
• Register your art submission by July 6
• Deliver artwork (clearly labeled with name and contact info) to the IBB front desk
  • July 15–17, between 8 a.m.-5 p.m. each day
  • Attendance at the July 23 Show is encouraged, but not required

⭐ Awards - All winning pieces to be displayed on the IBB website!

• Fan Favorite
  Voted on by IBB Art Gallery visitors from July 20–23. Celebrating the piece that resonates most with the community.
• 🔬 IBB ArtSci Award
  Recognizing a standout work that powerfully captures the intersection of art and science.
• 🧠 BRAINiArts Award
  Honoring creative expression inspired by neuroscience. 

Sponsored by Georgia Tech's Institute for Bioengineering and Bioscience (IBB), and the Bioengineering and Bioscience Unified Graduate Students (BBUGS)

He is Professor of Bioengineering and Materials Science at UC Berkeley and Faculty Scientist at Lawrence Berkeley National Laboratory. He is a Fellow of the Royal Society of Chemistry, the American Institute for Medical and Biological Engineering, the Materials Research Society and the American Association for the Advancement of Science. In addition to his research, he mentors and teaches students in the fields of biomaterials design, materials science, polymer science, and nanomedicine.

Faculty host: Felipe Quiroz

 

Special emphasis is given to Tissue Engineering and Regenerative Medicine and particular applications and more details are described on the lab web page.

Faculty host: Alexander Vlahos

 

BIO
Jeffrey Hubbell is a pioneer in the field of immuno-modulatory materials whose research spans biology, chemistry, and engineering to generate novel solutions to common health problems. His work focuses on using biomaterials and engineered proteins to enhance the body’s own immune system to fight inflammatory and autoimmune disorders, allergies, and disease states like cancers. With more than 400 papers and 100 issued US patents, Hubbell uses biomaterials and protein engineering approaches to investigate topics in regenerative medicine and immunotherapeutics. In regenerative medicine, he develops both materials and protein therapeutics to address issues such as chronic wound healing in diabetes and bone repair after trauma. In immunotherapeutics, he pursues nanomaterials in vaccination for infectious disease and cancer as well as targeted therapy with RNA, protein-material conjugates for inverse vaccines to induce antigen-specific tolerance in autoimmunity and allergy, and in protein therapy to tip immune balances toward aggression in immuno-oncology and toward tolerance in inflammatory disease. His interests are both basic and translational, having founded or co-founded six biomedical companies based on his technology.

Before moving to New York University, Hubbell was at the University of Chicago in the Pritzker School of Molecular Engineering, where he helped build its strength in immunoengineering. Prior to that, he was on the faculty of the Swiss Federal Institute of Technology Lausanne (EPFL, where he served as founding Director of the Institute of Bioengineering and Dean of the School of Life Sciences), the Swiss Federal Institute of Technology Zurich (ETHZ) and University of Zurich, the California Institute of Technology, and the University of Texas in Austin. He was elected to the US National Academy of Engineering in 2010, the National Academy of Medicine in 2019, the American Academy of Arts and Sciences in 2021, and the National Academy of Sciences in 2023.

Zoom link for virtual participation

Join us for lunch to learn how to better leverage the incredible resources available via your IBB Core Facilities! Lunch provided for registered attendees. 

Register to attend 

 

Register Here! Complimentary registration required for all attendees. 

Rapid-fire and poster presentation submission deadline April 29

Registration (without abstract submission) is open through May 14.

Conference Agenda

• 8:00 a.m. - Registration/Breakfast
• 9:00 a.m. - Opening Remarks
• 9:15 a.m. - Abigail Wojtowicz, Medical Director, US Medical Strategy, Takeda
• 10:00 a.m. - Tina Dorr, Partner, Barnes & Thornburg Law
• 10:30 a.m. - Poster Session
• 11:45 a.m. - Cherry Wan, Senior Manager, Chemical Science, Alcon
• 12:15 p.m. - Lunch
• 1:15 p.m. - Bruno Marques, Senior Vice President, Technical Operations, Morphocell Technologies
• 2:00 p.m. - Rapid Fire Talks
• 3:00 p.m - Rapid Fire Presentations
• 4:00 p.m. - Career Panel Discussion
• 5:00 p.m. - Closing Remarks
• 5:10 p.m. - Reception and Award Ceremony
• 7:00 p.m. - Adjourn

Join faculty from across the Georgia CTSA for an energetic and dynamic virtual networking session!

BIO
Marcela Maus grew up in New York, NY and attended Massachusetts Institute of Technology for her undergraduate degree in Biology and Literature. She then earned her MD, PhD from the University of Pennsylvania School of Medicine where she studied the biology of human T cell activation under the direction of her PhD mentor, Dr. Carl June. After completing her doctorate degrees, Marcela did a one-year postdoctoral fellowship with Dr. Kathy High at the Children’s Hospital of Philadelphia studying patient immune responses to liver-directed AAV-mediate gene transfer as a treatment for hemophilia. She then completed her clinical training in internal medicine, hematology, and oncology as a resident at the University of Pennsylvania Health System and a fellow at Memorial Sloan Kettering Cancer Center. While at Memorial Sloan Kettering, she worked in Michel Sadelain’s lab to engineer new genetically modified T cells to target the cancer-testis antigen NY-ESO-1 and received specialized training in Phase I developmental therapeutics. She was also awarded a K08 grant by the NIH to facilitate her transition to a faculty position.

Following her extensive training (11 years), Marcela returned to the University of Pennsylvania in 2012, where she was recruited by her former PhD mentor, to expand their research efforts in the development of CAR T cells for lymphoma, myeloma, and other cancers. While there, Marcela continued her efforts on preclinical development of CAR T cells and correlative studies of CAR T cell-related toxicities and resistance to therapies. They discovered and reported on the first cases of anaphylaxis to CAR T cells and off target cross-reactivity. She also led an entire arc of translational research, from preclinical testing to a first-in-human clinical trial of EGFRvIII CAR T cells for treatment of recurrent glioblastoma. Correlative data collected from this trial led to an understanding of CAR T resistant mechanisms that have led further refinement of these CAR T cells, which is one current area of focus in her current laboratory and has led to the development of another Phase I clinical trial for GBM patients.

Now, Dr. Maus is a Professor of Hematology and Oncology at Massachusetts General Hospital and Harvard Medical School, where she runs a laboratory focused on developing and improving CAR T cell therapy for cancer patients while also periodically attending for the bone marrow transplant service. Marcela is the Paula O-Keeffe Endowed Chair of the Massachusetts General Hospital Cancer Center and the Director of the Cellular Immunotherapy Program. She has won numerous awards for her transformative research and is achieving her goal of using science to determine the best way to treat patients by harnessing the power of the immune system to solve intractable problems like cancer. She also enjoys training clinicians and scientists and watching her mentees succeed and become independent scientists and collaborators.

Shawn Burke, Presenter

Establishing and maintaining a productive research team is a difficult challenge across all stages of an academic’s career. The science of good teamwork applies across an academic career: from incorporating graduate students and post-docs to your first research team to crossing-boundaries in the creation and maintenance of an interdisciplinary expert team. In conjunction with Georgia Clinical and Translational Science Alliance, we are offering a skill series to develop the skills necessary to build and maintain your research team by leveraging existing teams research. This workshop will focus on leadership within your team. Graduate students, post-docs, and all levels of academic faculty are all welcome to attend this workshop.

Team consult opportunity:

Our Team Science Skills presenters have graciously opened their schedules to provide a limited amount of attendees with direct feedback and guidance on their personal team issues. During a one-hour consulting session, attendees will be able to directly ask our experts questions and get personalized advice on how to effectively move their team forward.  Requesters must attend the full session and complete the post-evaluation survey to be eligible. 

• Do you have a patentable invention and want to protect it?
• Interested in commercializing your research either through licensing to an existing company or a startup?
• Want to learn about the commercialization resources available for entrepreneurs?

Stop by the IP and Commercialization Office Hours in the IBB atrium and meet with experts from the Office of Technology Licensing and Quadrant-i. We are at your service!  

The Experts:

• Cynthia Sundell, Senior Director of Life Sciences and Quadrant-i Principal
• Harold Solomon, Quadrant-i Principal
• Kashmira Kulkarni, Licensing Associate Office of Technology Licensing

• Do you have a patentable invention and want to protect it?
• Interested in commercializing your research either through licensing to an existing company or a startup?
• Want to learn about the commercialization resources available for entrepreneurs?

Stop by the IP and Commercialization Office Hours in the IBB atrium and meet with experts from the Office of Technology Licensing and Quadrant-i. We are at your service!  

The Experts:

• Cynthia Sundell, Senior Director of Life Sciences and Quadrant-i Principal
• Harold Solomon, Quadrant-i Principal
• Kashmira Kulkarni, Licensing Associate Office of Technology Licensing